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Abstract Atrial fibrillation (AF) and heart failure (HF) are both highly prevalent diseases and are accompanied by a significant
disease burden and increased mortality. Although the conditions may exist independently, they often go hand in
hand as each is able to provoke, sustain, and aggravate the other. In addition, the diseases share a risk profile with
several coinciding cardiovascular risk factors, promoting the odds of developing both AF and HF separately from
each other. When the diseases coexist, this provides additional challenges but also opportunities for the optimal
treatment. The recommended management of the comorbidities has been much debated in the past decades. In
this review, we describe the pathophysiological coherence of AF and HF, illustrate the current knowledge on the
management of them as comorbidities of each other and look forward to future developments in this field.
                                                                                                                                                                                                          
Keywords Atrial fibrillation • Heart failure • Tachycardiomyopathy • Pathophysiology • HFrEF • HFpEF •
Treatment • Catheter ablation • Pulmonary vein isolation
Introduction
Atrial fibrillation (AF) and heart failure (HF) are both highly prevalent
diseases, with an estimated number of 33 million individuals that are
affected by AF and 26 million by HF worldwide.1,2 The prevalence of
both diseases is expected to rise even further in the years to come as
a result of increased life expectancy and the increasing prevalence of
cardiovascular risk factors and underlying diseases; an alarming trend
given that both AF and HF are accompanied by significant morbidity
and mortality. Although the conditions may exist independently, they
often coexist as each is able to provoke, sustain, and aggravate the
other. They strongly affect each other’s outcome, with higher hospi-
talization rates and a two to three times increase in mortality risk
when compared with the separate diseases.3
Numerous studies have been conducted that aimed to elucidate
the complex pathophysiological mechanisms between AF and HF,
both with reduced (heart failure with reduced ejection fraction,
HFrEF) and preserved ejection fraction (heart failure with preserved
ejection fraction, HFpEF), and to discover the optimal treatment
strategy for the combination of both diseases. In this review, we de-
scribe the pathophysiological coherence of AF and HF, illustrate the
current knowledge on the management of them as comorbidities and
look to future developments in this field.
Pathophysiology
The increased risk of patients with AF to develop HF and vice versa,
is attributable to two factors. First, the diseases are inter-related
pathophysiologically and as such can provoke and sustain each other.
Secondly, both diseases share a risk profile with several coinciding
cardiovascular risk factors, increasing the odds of developing both
conditions separately from each other.
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Atrial fibrillation-induced heart failure
AF is able to provoke the development of HF via different mecha-
nisms. The arrhythmia causes several immediate haemodynamic
changes, which may contribute to decreased cardiac output and
acute HF. In addition, continuous AF or frequent AF paroxysms may
lead to persistent or irreversible structural changes causing impaired
systolic and diastolic function not only of the atria but also the ven-
tricles. Mechanisms responsible for the acute and chronic develop-
ment of HF in AF patients include loss of atrial contraction, irregular
heart rate, (persistent) tachycardia, neurohumoral activation, and
structural myocardial changes (Figure 1).
Loss of atrial contraction
In normal sinus rhythm, the atrial contraction contributes 20–25%
of the total left ventricular (LV) stroke volume, with maximum effect
at heart rates between 50 and 80 beats per minute. When diastolic
dysfunction is present, the contribution of the atrial contraction
becomes more important due to the decreased passive filling.4 As
such, the (sudden) loss of atrial contraction during AF episodes ac-
companied by the corresponding decrease in stroke volume can con-
tribute to the development of HF, especially in patients with diastolic
dysfunction.
Irregularity
The irregularity of ventricular contractions during AF may negatively
impact systolic and diastolic function, even when ventricular rates are
sufficiently treated with rate controlling drugs. This is partially caused
by the beat-to-beat variability in duration of the diastolic interval,
resulting in variable LV filling and end-diastolic volume. In addition,
shorter cycle lengths affect the filling and release of calcium from the
sarcoplasmic reticulum in greater extents than longer cycle lengths.
Hereby, the myocardial contractibility and total cardiac output during
irregular rhythms are decreased compared with regular rhythms with
the same average frequency.5
Tachycardia
In the absence of rhythm or rate modulating drugs, AF is often ac-
companied by high ventricular rates. Continuous high heart rates
may, independent of the cause of the tachycardia, lead to abnor-
mal calcium signalling between the cardiomyocyte surface mem-
brane and the sarcoplasmic reticulum, as well as decreased
calcium levels in the sarcoplasmic reticulum. The resulting altered
excitation–contraction coupling of the cardiomyocyte causes de-
creased myocardial contractility, smaller stroke volume, and LV
dilatation, also referred to as tachycardiomyopathy. Several ani-
mal studies demonstrated a correlation between a higher rate and
longer duration of rapid ventricular pacing and the severity of LV
systolic dysfunction.6 Both relatively short episodes of tachycardia
with high frequency and longer episodes with moderate frequen-
cies may thus cause tachycardiomyopathy.
Neurohumoral activation
The reduced cardiac output resulting from the loss of atrial contrac-
tion, irregularity, and tachycardia accompanying AF may cause
Figure 1 Pathophysiological relationship between atrial fibrillation and heart failure. AF, atrial fibrillation; HF, heart failure; RAAS, renin–angiotensin–
aldosterone system.
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activation of several neurohumoral pathways, including the renin–an-
giotensin–aldosterone system (RAAS) and adrenergic system.
Increased levels of angiotensin and aldosterone cause vasoconstric-
tion, fluid retention, and increased blood pressure. When elevated
during longer periods of time, however, RAAS hormones also lead to
structural changes including cardiomyocyte hypertrophy, apoptosis,
and adverse structural remodelling in the atrial and ventricular wall,
promoting the development of systolic and diastolic LV dysfunction.7
Additionally, the increased sympathetic stimulation during AF results
in increased contractility and heart rate in an attempt to maintain suf-
ficient cardiac output. Although this may be beneficial in the short
term, it may cause development and deterioration of HF in the long
term.
Structural myocardial changes
The combined effects of haemodynamic alterations and overacti-
vated regulatory mechanisms may cause permanent effects on the
structural integrity of the atrial and ventricular myocardium.
Although the systolic function of tachycardiomyopathy patients usu-
ally recovers when the arrhythmia is discontinued, prolonged AF may
cause permanent damage. The extracellular matrix is particularly sus-
ceptible to long-term changes such as interstitial fibrosis, i.e. in-
creased fibroblast activity and deposition of collagen and elastin
fibres. Notably, these interstitial adjustments predominantly develop
in the recovery phases between episodes of tachycardia, not during
the higher ventricular rates itself.8 Even in patients with normal LV
systolic ventricular function, cardiac magnetic resonance (CMR)
imaging in AF patients reveals increased levels of diffuse interstitial
ventricular fibrosis, associated with the AF burden but independent
of other risk factors such as ischaemic heart disease and systolic dys-
function.9 These remnants of the arrhythmia episodes may cause in-
creased LV stiffness and diastolic dysfunction.
Heart failure-induced atrial fibrillation
The increased risk of HF patients developing AF can primarily be
explained by structural atrial remodelling, mitral valve regurgitation,
and altered neurohumoral balances (Figure 1).
Structural remodelling of atria in heart failure
Both HFrEF and HFpEF are often associated with increased atrial fill-
ing pressures, although the mechanisms responsible may be different.
HFrEF is characterized by reduced LV ejection fraction and increased
end-diastolic LV volume. In HFpEF, the end-diastolic volume is usually
not increased, but LV relaxation is disturbed. The elevated LV pres-
sure in both types of HF causes increased atrial filling pressure, which
in turn lead to a cascade of structural changes in the atrial wall that
are strongly associated with AF.
The first step in this cascade is atrial dilatation and mechanical atrial
wall stretch due to the elevated atrial filling pressures. Wall stretch
may be present in strongly varying extents through different parts of
the atria, with peaks around the pulmonary vein ostia, LA appendage
ridge, the high posterior wall, anterior wall regions, and the septal
regions.10 Atrial stretch provokes atrial scarring and fibrosis, predom-
inantly in the areas where it is most severe. It is likely that atrial dilata-
tion and atrial fibrosis are important factors for the occurrence and
maintenance of AF. In dilated atria, multiple circuits coexist. Fibrosis
leads to inhomogeneities in conduction and refractoriness and the ar-
rhythmia itself causes persistent shortening of refractoriness. All of
these changes favour re-entry.11
Mitral regurgitation
Mitral regurgitation is common in HF, with different underlying etiol-
ogies for HFrEF and HFpEF. In HFrEF, structural ventricular remodel-
ling and LV dilatation may lead to secondary mitral regurgitation,
whereas HFpEF may induce atrial functional mitral regurgitation pre-
dominantly due to annular dilatation and anterior leaflet flattening.12
Moderate or severe mitral regurgitation causes left atrial volume and
pressure overload, resulting in increased local atrial wall stress, thus
promoting the development of AF. The severity of regurgitation is
correlated with the development of AF. Notably, AF itself may cause
atrial functional mitral regurgitation similar to the manner in which
HFpEF does, thereby indirectly sustaining itself.
Neurohumoral changes in heart failure
The decreased cardiac output during acute and chronic HF, similarly
to that during AF, often causes RAAS and sympathetic activation.
Besides their impact on HF development, these neurohumoral
changes promote atrial remodelling and increase susceptibility for AF
as well. The structural myocardial changes in the atria following in-
creased RAAS hormone levels lead to increased development and
sustenance of AF. Furthermore, sympathetic stimulation causes in-
creased early and delayed afterdepolarizations, increased focal firing
and favourable conditions for re-entry, thus increasing the suscepti-
bility for AF.13 Importantly, as these neurohumoral changes are both
a cause of and a result from AF as well as HF, a continuous process is
created in which the presence of (one of) the diseases may provoke
or deteriorate both itself and the other.
Mutual risk factors
Additionally, AF and HF share a common risk profile, increasing the
possibility of developing both conditions separately from each other.
Both HF and AF are more commonly seen in older patients with car-
diovascular risk factors such as hypertension, diabetes mellitus, obe-
sity, smoking, and sleep apnoea syndrome.
Hypertension and sleep apnoea may cause structural myocardial
changes such as LV hypertrophy and interstitial fibrosis, leading to in-
creased filling pressures and provoking the development of HF and
AF. Obesity, diabetes mellitus, and smoking cause a pro-inflammatory
state, creating an environment in which a patient is more susceptible
to both diseases.14 In addition, besides their direct effects these risk
factors contribute to the development of ischaemic heart disease,
which is one of the most prevalent causes of HF and is associated
with an increased risk of developing AF.15
Treatment considerations
Heart failure management
Standard treatment for HFrEF patients, independently of the pres-
ence or absence of AF, involves at least treatment with RAAS inhibi-
tors and beta-blockers (Figure 2).16 Given the close involvement of
the RAAS and the sympathetic nervous system in developing and
maintaining AF, treatment with inhibitors of these pathways are
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thought to not just inhibit HF progression, but also to reduce struc-
tural atrial remodelling and prevent AF in at-risk patients. Indeed,
these pharmacological interventions seem to have the potential to
reduce the rate of new-onset AF in this population. However, a
meta-analysis based on individual patient data comparing beta-
blockers with placebo in 1677 patients with concomitant HF and AF
did not demonstrate a beneficial effect, in contrast to HF patients in
sinus rhythm.17 This may be caused by the questionable positive ef-
fect of strict rate control in AF patients and the increased risk of lon-
ger pauses in excessive rate control.18,19 However, these findings did
not lead to changed treatment recommendations for AF patients in
the most recent guidelines.
For HFpEF, the optimal treatment strategy remains unclear. As no
single drug has yet demonstrated a survival benefit in this complex
and heterogeneous population, the cornerstone of the treatment of
these patients remains treatment of underlying comorbidities.16
Notably, up to 80% of HFpEF patients are still prescribed RAAS
inhibitors or beta-blockers, presumably mainly for the treatment of
common cardiovascular comorbidities such as hypertension and cor-
onary artery disease.
Risk factor management
There has been extensive research studying the effect of strict risk
factor management on AF burden. Positive effects from weight loss,
blood pressure management, lipid management, and treatment of ob-
structive sleep apnoea syndrome have been demonstrated in patients
with (lone) AF.14 In a population with both AF and HF, strict risk fac-
tor management reduced AF burden as well.20 Less is known about
the effect of risk factor management on HF in this population. In addi-
tion, the optimal target weight for patients with concomitant AF and
HF remains unclear. Although associated with a higher arrhythmia
burden in AF patients, obesity actually improves prognosis in the HF
population.21 This phenomenon has become known as the obesity
paradox, and its effect on prognosis of combined HF and AF remains
to be determined.
Atrial fibrillation management
AF can be treated with either rhythm control, i.e. attempting to main-
tain sinus rhythm, or rate control, i.e. allowing AF to persist but con-
trolling the frequency of ventricular contractions (Figure 2).22 In light
of the negative effect AF can have on HF, adopting a rhythm control
strategy would be expected to be beneficial in terms of survival and
disease progression. This theory is supported by the recently pub-
lished EAST trial, which confirmed the positive effects of rhythm con-
trol in patients with early AF.23 However, most antiarrhythmic drugs
are contraindicated in HF patients, providing a challenge to the pur-
suit of rhythm control in this patient category. The only available
options are amiodarone and dofetilide in HFrEF patients and amio-
darone, dronedarone, and dofetilide in HFpEF patients, while dofeti-
lide is not widely available in Europe.14 Amiodarone, although a
potent antiarrhythmic drug, is known for its extracardiac side-effects
and high discontinuation rate, limiting its low-threshold prescription.
Studies comparing rhythm and rate control in patients with AF and
HF did not demonstrate benefit of medication-based rhythm control
over rate control in terms of major clinical endpoints.24 A recent
meta-analysis comparing rhythm and rate control in a total of 2486
patients demonstrated comparable rates of mortality, stroke, and
thromboembolic events between the two groups.25 The hospitaliza-
tion rate was higher in the rhythm control arm, mainly driven by the
need for repeated cardioversion, adjustment of antiarrhythmic ther-
apy and adverse drug reactions. However, the lack of improvement
may be the limited efficacy of drugs in maintaining sinus rhythm, in ad-
dition to the harmful side-effects of currently available antiarrhythmic
therapies.
Catheter ablation in heart failure
patients with paroxysmal or persistent
atrial fibrillation
In light of these limitations of medical therapy, more potent options
to maintain sinus rhythm, such as invasive treatment with catheter
Figure 2 Treatment strategies for atrial fibrillation and heart failure. AF, atrial fibrillation; CRT, cardiac resynchronization therapy; HF, heart failure;
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator;
RAAS, renin–angiotensin–aldosterone system.
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ablation, might be effective to improve outcome. Considerable
advancements in this technique have been made in the past years and
it has proven to be an effective treatment to reduce AF burden and
complaints. Several observational studies investigated if these results
can be extrapolated to the HF population. Indeed, positive effects of
catheter ablation were demonstrated in HFrEF patients on important
surrogate outcomes such as LV ejection fraction, quality of life, and
exercise capability. Similar to in HFrEF, observational data of HFpEF
patients suggests that catheter ablation is associated with decreased
HF symptoms, as well as with regression of echocardiographic dia-
stolic dysfunction parameters.26 However, randomized trials con-
firming these promising results are not yet available in the HFpEF
population.
In the HFrEF population, the first randomized trial comparing cath-
eter ablation with pharmacological treatment was published in
2011.27 This small study in 38 patients did not demonstrate an im-
provement on the primary endpoint of LV ejection fraction following
catheter ablation compared with pharmacological rate control.
However, this lack of effect might be attributable to the modest suc-
cess percentage of maintaining sinus rhythm of only 50%. In subse-
quent randomized studies, which all achieved higher success
rates from catheter ablation, positive results on LV ejection fraction,
improved functional capacity, and quality of life were demon-
strated.28–30
In 2016, the AATAC trial demonstrated a trend towards lower
mortality and hospitalizations following catheter ablation when com-
pared with amiodarone, although the study was not powered to
demonstrate significant effects.31 After these promising results, the
outcomes of the CASTLE-AF were eagerly awaited, as this was the
first sufficiently powered study to demonstrate possible effects on
clinical endpoints. Indeed, the CASTLE-AF described an important
reduction in the composite endpoint of death and HF
hospitalizations, from 44.6% in the standard medical therapy group to
28.5% in the AF ablation group [hazard ratio 0.62 (0.43–0.87)].32 In
contrast, the most recent study comparing catheter ablation with
pharmacological treatment, the CABANA trial, did not demonstrate
a significant difference in the primary composite endpoint of
mortality, disabling stroke, serious bleeding, or cardiac arrest
between the two groups.33
A meta-analysis combining efficacy data of all seven aforemen-
tioned randomized trials found that catheter ablation was associated
with significantly lower mortality (relative risk reduction of 49%), hos-
pitalization (relative risk reduction of 56%), improved LV ejection
fraction, and improved quality of life.25 Still, it is important to note
that the positive reported effects of catheter ablation are strongly de-
pendent on several factors, such as patient characteristics, HF aetiol-
ogy, follow-up duration, and ablation strategy (Figure 3). Hence,
although catheter ablation has demonstrated favourable effects on
important clinical endpoints, as well as functional status and quality of
life, careful patient selection, and selection of ablation technique
remains a point of attention.
Pace and ablate (rate control) in heart
failure patients with permanent atrial
fibrillation
For patients with permanent AF, a pace and ablate strategy [atrioven-
tricular junction ablation combined with cardiac resynchronization
therapy (CRT)] may be considered. In this strategy the persistence of
AF and the associated loss of atrial contractions is accepted, while
biventricular pacing assures strict rate control and regular ventricular
contractions. Several studies have demonstrated markedly improved
HF outcomes of a pace and ablate strategy compared with pharma-
cological rate control in patients with and without a previous CRT in-
dication.34 However, when pace and ablate is compared with
Figure 3 Therapy choice for atrial fibrillation and concomitant heart failure. AAD, antiarrhythmic drugs; AF, atrial fibrillation; HF, heart failure,
NYHA, New York Heart Association.
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catheter ablation aimed to achieve rhythm control, rhythm control
demonstrated superior results. Therefore, it seems reasonable to re-
serve a pace and ablate strategy for those patients in whom catheter
ablation is expected to be ineffective (e.g. due to comorbidities, se-
verely dilated atria or permanent AF) or in whom previous catheter
ablation has failed (Figure 3).
Conclusion
The optimal therapy for coexisting AF an HF remains a topic of de-
bate. In light of the harmful effect AF can have on HF, adopting a
rhythm control strategy could be expected to be beneficial in terms
of survival and disease progression. However, pharmacological
rhythm control does not lead to significant health gain when com-
pared with rate control in this patient population. Catheter ablation
is an effective option to achieve rhythm control without the unfav-
ourable effects of antiarrhythmic drugs, and seems to improve the
HF prognosis as well. However, several unaddressed questions re-
main in spite of the current evidence, in particular with regards to the
optimal patient selection for this invasive therapy. Further studies
with long-term follow-up may clarify the remaining uncertainties.
Conflict of interest: none declared.
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